EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The dual diversity crisis in alzheimer's disease research: why neuroimaging biomarkers and clinical trials keep failing

Thorsten Rudroff iD

GeroScience · 06.07.2026 · 48 (5) · 6431-6436

DOI: 10.1007/s11357-026-02400-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift GeroScience, online erschienen am 06.07.2026. Verfasst von Thorsten Rudroff. Beteiligte Einrichtung: Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland. thrudr@utu.fi. Hauptthemen laut MEDLINE: Alzheimer Disease, Neuroimaging, Clinical Trials as Topic, Biomedical Research. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Turku.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease clinical trials have failed at a rate exceeding 99% over two decades, and neuroimaging biomarkers developed in discovery cohorts have repeatedly disappointed in validation and clinical application. Standard explanations address symptoms rather than structural causes. I argue that Alzheimer's disease research is caught in a Dual Diversity Crisis: the simultaneous neglect of population diversity and individual neurobiological heterogeneity as compounding validity threats. The first dimension concerns the systematic over-reliance on Western, young, healthy, and university-affiliated (WYHU) research samples, from which biomarker normative standards are derived and then applied universally to a demographically distinct clinical population. The second concerns the erasure, through group-level analysis, of the substantial neurobiological heterogeneity that exists within any sample regardless of its demographic composition. The critical structural insight is that these two problems do not add; they multiply. A WYHU-derived group average is doubly unrepresentative: it misrepresents the target population demographically and conceals the individual variance that exists even within that already-unrepresentative sample. FDG-PET evidence demonstrates that biological sex accounts for approximately 30 times more metabolic variance than diagnostic category in patients with equivalent symptom profiles, directly challenging the construct validity of threshold-based trial inclusion. Correcting the Dual Diversity Crisis requires treating demographic diversity and individual neurobiological characterization as primary design parameters, not post-hoc corrections. Until this reconceptualization occurs, translational failure in Alzheimer's disease research remains the structurally expected outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseNeuroimagingClinical Trials as TopicBiomedical ResearchHumansBiomarkersPositron-Emission TomographyFemale

Stichwörter der Autor:innen

Alzheimer’s diseaseNeuroimaging biomarkersWYHU research

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland. thrudr@utu.fi.

ORCID-Profile: Thorsten Rudroff

Förderung

  • University of Turku

Zitieren

APA

Rudroff, T. (2026). The dual diversity crisis in alzheimer's disease research: why neuroimaging biomarkers and clinical trials keep failing. GeroScience, 48(5), 6431-6436. https://doi.org/10.1007/s11357-026-02400-x

Vancouver

Rudroff T. The dual diversity crisis in alzheimer's disease research: why neuroimaging biomarkers and clinical trials keep failing. GeroScience. 2026;48(5):6431-6436. doi:10.1007/s11357-026-02400-x

BibTeX
@article{Rudroff2026,
  author = {Rudroff, Thorsten},
  title = {The dual diversity crisis in alzheimer's disease research: why neuroimaging biomarkers and clinical trials keep failing},
  journal = {GeroScience},
  year = {2026},
  volume = {48},
  number = {5},
  pages = {6431--6436},
  doi = {10.1007/s11357-026-02400-x}
}
Kostenlos starten →